

23 January 2006

Mr S Gregson
General Manager, Adjudication Branch
Australian Competitive & Consumer Commission
PO Box 1199
Dickson ACT 2602

Fax (02) 6243 1211

Dear Mr Gregson,

Re: Medicines Australia Revised Code of Conduct (A90994-6)

Sanofi-aventis supports the Medicines Australia submission for authorisation of the 15th edition of the Medicines Australia Code of Conduct (the Code). The changes follow a lengthy and widespread consultation process.

Sanofi-aventis also wishes to state its support for the proposed change to Section 9.4 of the Code (and accompanying explanatory note) relating to promotion of devices. We do not consider the changes are "detrimental to competition" as proposed by Novo Nordisk in their letter dated 15th December. On the contrary, we believe that promotion of insulin devices that can only be used with a limited range of prescription insulin's that are only provided by a single sponsor amounts to promotion of that insulin or similar range of insulin's. We consider the proposed changes are appropriate in this regard and also support the comments provided on behalf of Medicines Australia by Allens Arthur Robinson in their letter of 9th January 2006.

Yours sincerely
Sanofi-aventis

Leah Goodman
Director - Diabetes